Medicaid expansion under the Affordable Care Act (ACA) is associated with better outcomes for patients with hormone receptor (HR)-negative, human...

HER2-targeted therapies, originally developed for breast cancer, may also benefit patients with rare bile duct cancer and HER2-mutated breast...

THURSDAY, Oct. 31, 2024 -- Inavolisib plus palbociclib-fulvestrant yields significantly longer progression-free survival than placebo plus...

FRIDAY, Oct. 25, 2024 -- Expanding Medicaid is associated with an increase in receipt of guideline-concordant treatment among nonelderly women newly...

Drugs aimed at HER2-positive breast cancer may also help certain patients with bile duct cancer, as indicated by findings from a patient trial that...

Ludwig Cancer Research scientists have developed a full, start-to-finish computational pipeline that integrates multiple molecular and genetic...

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with...

A study published in Clinical Cancer Research confirmed that tissue stiffening in the most common types of breast cancer, HER2-negative, can directly...

Tissue stiffness in HER2-negative breast cancer, the most common type, can directly contribute to disease progression and metastasis, which can have...